Annovis Bio financials
$1.30−5.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$29.7M | -$26.7M | -$45.0M | -$25.5M | -$14.5M | -$6.6M |
| Net income | -$28.9M | -$24.6M | -$56.2M | -$25.3M | -$14.5M | -$5.5M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-1.40 | $-2.31 | $-6.23 | $-3.10 | $-1.90 | $-0.87 |
| EBITDA | -$29.7M | -$26.7M | -$45.0M | -$25.5M | -$14.5M | -$6.6M |
| Operating cash flow | -$25.6M | -$21.9M | -$40.0M | -$17.3M | -$9.1M | -$4.0M |
| Free cash flow | -$25.6M | -$21.9M | -$40.0M | -$17.3M | — | — |
| Diluted shares | 20.6M | 12.2M | 9.0M | 8.2M | 7.6M | 6.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $19.5M | $10.6M | $5.8M | $28.4M | $45.7M | $8.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $21.1M | $13.9M | $10.2M | $36.0M | $46.0M | $8.1M |
| Total liabilities | $4.2M | $4.6M | $18.0M | $7.7M | $1.5M | $578.4K |
| Shareholders' equity | $16.9M | $9.3M | -$7.8M | $28.3M | $44.5M | $7.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology